|
|
Article: DOR BioPharma Will Advance orBec To Phase II Trials For Irritable Bowel Syndrome; Decision To Pursue Second Indication Follows Positive Results In Animal Models.
- Article from:
- Business Wire
- Article date:
- June 19, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
LAKE FOREST, Ill.--(BUSINESS WIRE)--June 19, 2003
DOR BioPharma Inc. (AMEX:DOR) (the "Company" or "DOR") announced that the Company's lead product orBec(R) has demonstrated positive results in preliminary experiments with animal models of Irritable Bowel Syndrome (IBS)-like pain. Based on these positive findings, DOR is planning to conduct a Phase II clinical trial in patients who suffer from post-infection IBS.
Ralph Ellison, MD, Chief Executive Officer and President of DOR stated, "IBS affects approximately 35 million patients per year in the U.S. and represents a significant market opportunity for ...